- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06111079
Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia
December 18, 2023 updated by: FANG HE
Aspirin Discontinuation at 28 or 36 Weeks' Gestation in High-Risk Pregnant Women of Preeclampsia A Randomized Clinical Trial
Low-dose aspirin (LDA) is considered to be the most effective agent to prevent preeclampsia (PE).
At present, there is little exploration about the timing of aspirin discontinuation.
Most international guidelines default until 36 weeks of gestation or delivery.
China Guideline (2020) recommended that aspirin should be preventively used until 26-28 weeks of gestation, but there was little direct evidence.
According to the two-stage theory, placental dysplasia before 28 weeks of gestation is the key to developing PE, the significance of aspirin use after 28 weeks of gestation is debatable.
If aspirin discontinuation at 28 weeks of gestation is proven to be feasible for preventing preterm PE, it will not only reduce the risk of Perinatal Haemorrhage but also save medical expenses.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study aimed to optimize the strategy of aspirin to prevent preeclampsia, by exploring whether aspirin discontinuation at 28 weeks of gestation to prevent preterm PE is not inferior to 36 weeks of gestation.
We will include pregnant women with normal NT scan who meet at least one high-risk factor or at least two medium-risk factors.
During 12-16 weeks of gestation, the mean arterial pressure (MAP) and placental growth factor (PlGF) are measured, then initiating aspirin 100mg qn.
At 24-27+6 weeks of gestation, the patients were 1:1 randomly divided into two groups, sFlt-1 and PlGF were detected at the same time.
The experimental group discontinue aspirin at 28 weeks of gestation, and the control group receive aspirin until 36 weeks of gestation.
The incidence of preterm PE in the two groups was compared by non-inferiority test, and the non-inferiority threshold was 2%.
Study Type
Interventional
Enrollment (Estimated)
1800
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fang He, M.D
- Phone Number: +86 13724831279
- Email: hefangjnu@126.com
Study Contact Backup
- Name: Qingwen Nie, Master
- Phone Number: +86 15622149953
- Email: qw0621n@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510150
- Recruiting
- FANG HE
-
Contact:
- FANG HE, M.D
- Phone Number: 13724831279
- Email: hefangjnu@126.com
-
Contact:
- Qingwen Nie, Master
- Phone Number: 15622149953
- Email: qw0621n@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- At <16 weeks of gestation, normal NT scan
- At least 1 high risk factor or at least 2 moderate risk factors
- Intend to receive prenatal examination and deliver in this institution
- Signed a written informed consent for participation in the study
Exclusion Criteria:
- Aspirin initiated after 16 week
- Intolerant or allergic to aspirin
- Aspirin adherence was <80%
- Miscarriage or termination of pregnancy before randomization
- drop out (do not return to the hospital for delivery).
- Lost to follow-up
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aspirin discontinuation group
initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, discontinuing aspirin at 28 weeks of gestation.
|
Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
Other Names:
|
Active Comparator: Control group
initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, continuing aspirin until 36 weeks of gestation.
|
Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of preterm preeclampsia
Time Frame: Within one week after delivery
|
delivery with preeclampsia before 37 weeks of gestation
|
Within one week after delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of early-onset preeclampsia
Time Frame: Within one week after delivery
|
delivery with preeclampsia before 34 weeks of gestation
|
Within one week after delivery
|
Incidence of term preeclampsia
Time Frame: Within one week after delivery
|
delivery with preeclampsia after 37 weeks of gestation
|
Within one week after delivery
|
Incidence of gestational hypertension
Time Frame: Within one week after delivery
|
new onset of high blood pressure after 20 weeks of gestation (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg)
|
Within one week after delivery
|
Incidence of small for gestational age
Time Frame: Within one week after delivery
|
birth weight below the 10th percentile
|
Within one week after delivery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fang He, M.D, The Third Affiliated Hospital of Guangzhou Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2023
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
October 23, 2023
First Submitted That Met QC Criteria
October 26, 2023
First Posted (Actual)
November 1, 2023
Study Record Updates
Last Update Posted (Estimated)
December 19, 2023
Last Update Submitted That Met QC Criteria
December 18, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Pregnancy Complications
- Hypertension, Pregnancy-Induced
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Hemorrhage
- Pre-Eclampsia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- [2023] Ethics Review NO.118
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Preeclampsia
-
MemorialCare Health SystemNot yet recruitingPreeclampsia | Preeclampsia Postpartum | Preeclampsia Severe | Preeclampsia Mild
-
Christiana Care Health ServicesActive, not recruitingPre-Eclampsia | Preeclampsia | Preterm | Preeclampsia Severe | Preeclampsia Second Trimester | Preeclampsia Complicating Childbirth | Preeclampsia PuerperiumUnited States
-
University Medical Centre LjubljanaCompletedPreeclampsia Postpartum | Preeclampsia SevereSlovenia
-
Cedars-Sinai Medical CenterThermoFisher Scientific Brahms Biomarkers FranceCompletedGestational Hypertension | Preeclampsia Severe | Preeclampsia and Eclampsia | Chronic Hypertension in Obstetric Context | Superimposed Pre-Eclampsia | Preeclampsia MildUnited States
-
Washington University School of MedicineRecruitingPreeclampsia Postpartum | Preeclampsia SevereUnited States
-
Brigham and Women's HospitalCompletedHypertension in Pregnancy | Postpartum | Postpartum Preeclampsia | Gestational Hypertension | Preeclampsia SevereUnited States
-
Christiana Care Health ServicesNot yet recruitingPreterm Birth Complication | Preeclampsia Severe | Preeclampsia Second TrimesterUnited States
-
AMAG Pharmaceuticals, Inc.TerminatedSevere PreeclampsiaUnited States, Poland, South Africa
-
Mpilo Central HospitalCompletedSevere PreeclampsiaZimbabwe
Clinical Trials on aspirin discontinuation
-
Assistance Publique - Hôpitaux de ParisCompletedAdult Pulmonary Langerhans Cell HistiocytosisFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Pierre and...Unknown
-
University of ZurichCompletedSkin CancerSwitzerland
-
Seoul National University HospitalCompletedCoronary Artery DiseaseKorea, Republic of
-
University of CopenhagenDeerland Probiotics and EnzymesCompleted
-
University of Texas at AustinRecruitingPelvic Organ Prolapse | Stress Urinary Incontinence | Urinary Retention | Catheter Related ComplicationUnited States
-
West Virginia UniversityRecruiting
-
Josep Rodes-CabauRecruitingIschemic Stroke | Patent Foramen Ovale | Bleeding UlcerCanada
-
University of ChicagoRecruitingMultiple MyelomaUnited States
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentActive, not recruiting